We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Shield Therapeutics Plc | STX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.90 | 08:00:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.90 | 2.90 | 2.90 | 2.90 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 24/1/2025 14:24 by purchaseatthetop 51k at $210 in Q4 and I think we hit 4.5p. The moment investors can see cash generation we go skywards. |
Posted at 16/1/2025 10:33 by socionomics "Socionomics 19 Jul '24 - 11:25 - 14011 of 15791 EditYep, and if the prescription levels have increased along the same lines as the UK numbers, we could be in for the long anticipated re-rate. AOP offered 6.2p per share. What's happened since we rejected that offer? The prescriptions are increasing exponentially, £4M upfront payment in the bank, and branching out into new jurisdictions. If we were steadily moving higher in the 10-20p range, nobody would question it, but because we're languishing down here, investors seem reluctant. Go figure! Easy money this one, just have to wait a week or two." |
Posted at 13/1/2025 19:00 by skcots48 So for long term holders rather than new investors what exactly do you propose we do to be careful?.Our mistakes were made long ago not to get out.And if it goes at 3p I've got to own it.For new investors they can get in at 2.5p so they have minimal ability to lose if AOP come in.If they don't come in it's because they're hitting their targets and we all make money.Well that's my take |
Posted at 13/1/2025 11:40 by zeus19 A friend of mine emailed investor relations querying the lack of holdings RNS. This was their responseMany thanks for your email. I hope to be able to assist you with your enquiry. In regards to the recent fundraise I can confirm that the number of shares in issues is as stated on our website (1,041,690,484) and this is confirmed by the filing with Companies House and AIM in regards to the allotment of shares issued. AIM Rule 26 | Shield Therapeutics plc (link) SH01 Return of Allotment of Shares (link) Unfortunately we do not have control over the postings on the London Stock Exchange but will however bring this to their attention. In regards to the holdings RNS you refer to, we can confirm that this was included within the RNS published on the 24th December 2024 which also included the details of the results of the General Meeting and the Tita Voting Rights. Result of General Meeting & Total Voting Rights | Shield Therapeutics plc I hope I have been able to assist you but please do not hesitate to contact me should this not be the case. |
Posted at 13/1/2025 09:09 by skcots48 Although of course I recognise investors - traders might stay clear of higher risk companies in these times |
Posted at 03/1/2025 10:11 by emigno2020 11 of the last 15 posts have been from purchaseatthetop. All feels a bit desperate given that most investors know they won’t get their money back and are nursing huge losses. |
Posted at 13/11/2024 17:51 by purchaseatthetop Shield Therapeutics plcShield Therapeutics plc5,423 followers5,423 followers 2h • Edited • 2 hours ago On 14 November, Anders Lundstrom, Interim CEO, and Santosh Shanbhag, CFO, will be joining the panel for the Hardman & Co Investor Forum. We look forward to discussing the impact of changes in the global markets on healthcare investments and exploring new growth avenues in the sector. Join us as we share our insights and connect with fellow investors and industry experts. Register now to participate, ask questions, and gain valuable insights here: |
Posted at 05/11/2024 08:26 by reviewwworld Outside of AOP and possibly Nestle there aren't institutional investors. Those other major holdings are you and I ie retail investors with holdings reflected in aggregate at the brokerage level. |
Posted at 11/10/2024 11:10 by qipincha I don't think individual has that much influence.I use advfn for 10+ years when bb has more posts, it attracts more investors, but I don't think it affect investors that much. most investors are sensible these days and do not follow other's comments blindly. And more importantly, the performance of a company will not be affected by what we said here. I have followed stx for 2-3 years, from 6p to 12p and down to 1.4p and now back to 4.3p (today). Really need a big heart! I would possibly sold out if I don't know the background and potential of the company when it drop down to 1.4p. But glad I took a different action. Now, the company still has a little bit of uncertainty, but much less risk comparing to two years ago. Hence the price moving up since summer. many of us here believe the company is still significant undervalued. Why? Revenue is $30m+ and market cap only $40m, and growth rate is high (20% quarterly). ok, no more, do your own research so you know what you are doing. |
Posted at 10/8/2024 11:49 by hpcg I can tell none of you spread bet. There isn't a short market in a tiddler like STX. Providers don't offer it, long or short. Companies of this size are a distraction with no source of profit. If there any shorts they will be in physical shares at small brokers. Now I admit I know nothing about having a broker as I invest solely through nominee accounts and spread bets so I have no idea if even that is the case. If it is then those people will be somewhat professional and understand the risks. Shorting anything with a sub £50mn market cap is extremely high risk.The share price over the long term has been and is still 100% dictated by fundamentals. The past - can't sell enough product to run the company, never mind make a profit. Now, indications that it soon will be able to sell enough to first cover costs and then to make a profit. This is not certain. Investors however can discount that because the capitalisation is so low that even a modest profit would see a decent return to 2035. Even more so it investors can discount some of the projections made in e.g. 2021 (below). Personally for now I'm treating that as fantasy, the pricing more so than the TAM, but I cannot dismiss it entirely. So for the new investor the risk reward looks enticing and thus the share price rises. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
